AST2818 mesylate (Synonyms: AST2818) |
| Catalog No.GC33096 |
Alflutinib(Furmonertinib) mesylate는 EGFR의 강력한 억제제입니다. Alflutinib(Furmonertinib) mesylate는 EGFR 활성 돌연변이와 T790M 획득 내성 돌연변이를 억제합니다. 알플루티닙(Furmonertinib) 메실레이트는 암 질환, 특히 비소세포폐암(NSCLC) 연구에 대한 잠재력이 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2130958-55-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AST2818 mesylate is an EGFR inhibitor.
AST2818 mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation[1].
[1]. Y.Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial. J Thorac Oncol. 2017 Nov, 12(11): S2138.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *